Home » Articles » Therapeutic overviews

Therapeutic overviews and drug discovery

Therapeutic overviews and drug discovery

Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates [27/10/03]
The autoimmune diseases are receiving increasing attention in the pharmaceutical industry as progress is made in the understanding of immune and inflammatory processes. It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition.This report considers almost 50 molecular targets and more than 150 products being developed for rheumatoid arthritis by nearly 100 companies therefore representing not only a complete analysis of current areas of research activity but also a thorough examination of therapeutic candidates emerging from this activity.

Asthma Therapeutics: New treatment options and emerging drug discovery targets [27/10/03]
From 1980 to 1996, the number of Americans afflicted with asthma more than doubled to almost 15 million, with children under five years old experiencing the highest rate of increase. Considerable effort is being directed towards the identification of new molecular targets for the improved treatment of asthma. This report describes the proof of concept data and offers expert opinion on each of these targets. The report also profiles therapeutics on the market or in development.

Retinoids : An A-Z guide to their biology, therapeutic opportunities & pharmaceutical development [27/10/03]
The retinoids play a key role in differentiation, proliferation and apoptosis and as a result over 30 naturally occurring and synthetic analogs of retinoic acid are now either in development or on the market. This dossier represents one of the most comprehensive insights into the retinoid field published in recent years. The aim of this report is to bring the reader up to date with advances in this area, pharmaceutical activity relating to retinoid development and strategies that will lead to the identification of improved retinoids.

Therapeutic & pharmaceutical opportunities for osteoporosis and atherosclerosis [27/10/03]
An estimated 10 million Americans over the age of 50 years old suffer from osteoporosis and a further 32.9 million have low bone mass, placing them at an increased risk for developing this condition. This report reviews the physiology of bone turnover as well as the etiology, epidemiology and treatment options relating to osteoporosis. The dossier continues with a full analysis of vitamin K and how its role in both bone health and cardiovascular function may result in vitamin K mimics contributing to a future breakthrough in osteoporosis therapeutics. Concluding with an in depth account of the osteoporosis market, development activity within this sector and full profiles of companies involved in this development, the report allows a full understanding of the osteoporosis field. .

5-HT7 antagonists: Novel molecules for the unmet migraine prophylaxis market [27/10/03]
The migraine market was revolutionized by the launch of the prototypic triptan, sumatriptan in the early 1990's. The triptans are acute therapies of migraine aborting an attack once it has started rather than preventing it. According to current guidelines 15% of sufferers would benefit from prophylactic treatment however the availability of molecules that effectively prevent migraine attacks with an acceptable tolerability profile is extremely limited. 5-HT7 receptor antagonists offer an effective approach to the unmet field of migraine prophylaxis. Additional evidence exists to support the use of antagonists to treat a second unmet market, schizophrenia, while agonists may have therapeutic value in the treatment of cardiovascular disorders and depression. This report provides a state of the art of the 5-HT7 receptor. With a focus of migraine prophylaxis this report describes the proof of concept supporting its therapeutic potential in relation to these indications and analyzes current pharmaceutical activity surrounding the development of 5-HT7 ligands.

Targeting endogenous inhibitors of apoptosis: Opportunities for the treatment of cancer, stroke and MS [27/10/03]
It is now well established that cellular suicide (apoptosis or programmed cell death) is central to a number of physiological cellular processes and is essential in the maintenance of homeostasis and survival of multicellular organisms. This dossier opens with a general introduction to the apoptosis pathway and the function of members of the IAP family, an emerging target for apoptosis-related pharmaceuticals. The report then continues with a description of the role of the IAPs in cancer, stroke and angiogenesis.

Glycogen synthase kinase 3 inhibitors:Proof of concept and therapeutic opportunities for the treatment of diabetes, Alzheimer's disease, stroke & bipolar disorder [27/10/03]
Since the mid-1990s there has been a near exponential rise in the level of glycogen synthase kinase-3 (GSK-3) related research. The present report, produced by LeadDiscovery analysts under the editorial guidance of field-leader, Dr Hagit Eldar-Finkelman, offers a state of the art overview of GSK-3 and analyses the therapeutic role that inhibitors of this enzyme may play.

Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression [27/10/03]
Mental disorders affect 44.3 million Americans in a given year. According to analysts the current global CNS therapeutics market is estimated at $40-55 billion, accounting for around 15% of the total global pharmaceuticals market. This report overviews the proof of concept for targeting central angiotensin receptors for the treatment of anxiety, depression and Alzheimer's disease and therefore bridges the hypertension and CNS markets.

Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets [27/10/03]
In March, 1998, Pfizer launched sildenafil (Viagra) for the treatment of erectile dysfunction. This move had an explosive effect on Pfizer's financial figures. This report analyzes both the science and the pharmaceutical activity surrounding male and female sexual dysfunction, focusing on novel pharmacological targets for these conditions.

Histone deacetylase inhibitors: Redefining pharmaceutical approaches to the treatment of cancer
The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has been driven by the ability of HDAC inhibitors to modulate transcriptional activity. HDAC inhibitors have the potential to occupy an indomitable position in the fast-moving cytostatic market. LeadDiscovery, Dr Chris Berrie and Dr Victoria Richon (Executive Director of Biology, Aton Pharma and HDAC field-leader) have collaborated to produce one of the most comprehensive reviews of HDAC research, pharmaceutical opportunities, and current and future drug development strategies.

Ghrelin: The future of obesity therapeutics? [27/10/03]
lt is estimated that somewhere between 34 and 61 million people in the US are obese and in much of the developing world this incidence is increasing by about 1% per year. Ghrelin represents one of the most promising targets to emerge in the field of metabolic disorders. This report offers a fully up to date evaluation of ghrelin as a target for metabolic disorders and describes its additional roles in cardiovascular disease; it identifies pharmaceutical activity relating to the development of ghrelin modulators; it analyses the most recent patent activity in this field; and it places all of this activity in the context of the rapidly expanding area of anti-obesity therapeutics.

Disclaimer

Net Media Marketing excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. Net Media Marketing will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. Net Media Marketing makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.

All jobs & Vacancies, Pharmaceutical sales jobs, Healthcare sales jobs, Laboratory sales jobs, Veterinary sales jobs, Dental sales jobs, Trainee medical sales jobs, Nurse Advisor jobs, Sales Management jobs, Marketing jobs, Senior Management jobs, Regulatory & Clinical jobs, Scientific Sales Jobs, Pharmaceutical jobs, Pharmaceutical Company, British National Formulary (BNF), British Pharmacopoeia (BP), NHS News, NHS Articles

Home | Contact | Legal | Privacy | Free text | Personality test | Best broadband deals | CV Advice